Current Approaches to Design Space Development and Regulatory Applications for Drug Products: Findings from the IQ Utilization of Design Space for Filings Working Group Survey
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03765-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von James E Miesle und 10 weiteren Autor:innen. Beteiligte Einrichtung: Synthetic Molecule Design and Development, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. miesleje@lilly.com. Hauptthemen laut MEDLINE: Drug Industry, Drug Development. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The concept of a Design Space (DSp) was introduced in ICH Q8 as a tool within the quality-by-design (QbD) approach to pharmaceutical development with the intent of being globally applicable. However, there appears to be variance in the regulatory agency expectations in pharmaceutical product filing and implementation of DSp. This paper presents some of the current industry perspective on design space. METHODS: The Utilization of Design Space for Filings (UDSpF) Working Group in the Innovation and Quality (IQ) Consortium conducted a survey to establish a baseline for the current understanding of DSp among IQ member companies and assess the similarities and/or differences in strategies when filing a DSp. The survey focused on how IQ member companies approach DSp development, the primary drivers for the DSp, the presentation of the DSp in the filing, DSp verification and the benefits and flexibility anticipated and/or realized. RESULTS: A total of 14 responses were received and analyzed representing a small sample size but a large proportion of the innovator industry/large pharmaceutical companies. The survey results revealed that DSp is not yet a commonplace for small molecule drug products and may not even be utilized as much in large molecule drug products. The benefits of DSp, with respect to enhanced process understanding, are well understood by the sponsors; however, the benefits of filed DSp with respect to manufacturing flexibility are not fully realized in the commercial lifecycle of the product. There are also challenges in gaining consistent buy-in/value proposition for DSp among cross-functional teams within organizations. CONCLUSIONS: There are still gaps in design space implementation for its full benefit in the pharmaceutical industry. The WG has presented a unified view from member companies on the approach to DSp considering when/where the DSp experiments are conducted and on the extent of the DSp development proposed in a dossier.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Synthetic Molecule Design and Development, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. miesleje@lilly.com.
- Pharmaceutical Development, Biogen, Cambridge, MA, USA.
- Biologics Drug Product Development, Sanofi, Frankfurt, Germany.
- Product Development Science & Technology, Abbvie, North Chicago, IL, USA.
- Biologics Drug Product Development, Teva Branded Pharmaceuticals, West Chester, PA, USA.
- Technical Services/Manufacturing Science, Eli Lilly and Company, Indianapolis, IN, USA.
Zitieren
APA
Miesle, J. E., Osei-Yeboah, F., Pauli-Bruns, A., Chen, B., Manceva, S., Wade, J. B., Yin, S., Desai, D., Dirat, O., Bhugra, C., & Stauffer, F. (2024). Current Approaches to Design Space Development and Regulatory Applications for Drug Products: Findings from the IQ Utilization of Design Space for Filings Working Group Survey. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03765-4
Vancouver
Miesle JE, Osei-Yeboah F, Pauli-Bruns A, Chen B, Manceva S, Wade JB, et al. Current Approaches to Design Space Development and Regulatory Applications for Drug Products: Findings from the IQ Utilization of Design Space for Filings Working Group Survey. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03765-4
BibTeX
@article{Miesle2024,
author = {Miesle, James E and Osei-Yeboah, Frederick and Pauli-Bruns, Anette and Chen, Bei and Manceva, Slobodanka and Wade, Jonathan B and Yin, Shawn and Desai, Divyakant and Dirat, Olivier and Bhugra, Chandan and Stauffer, Fanny},
title = {Current Approaches to Design Space Development and Regulatory Applications for Drug Products: Findings from the IQ Utilization of Design Space for Filings Working Group Survey},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03765-4}
}
EUVIMED